Pfizer completes divestiture of ViiV Healthcare stake

Pfizer has completed the divestiture of its stake in ViiV Healthcare, an HIV-focused joint venture. ViiV issued new shares to Shionogi for $2.125 billion, cancelling Pfizer's equity holding; Pfizer received $1.875 billion, GSK received a $0.250 billion special dividend, and a Pfizer put option liability was extinguished.

Detected & updated continuously · Source: Nebula